Our Story

BiBo Pharma is a full spectrum CDMO covering the entire CMC lifecycle of biologics. BiBo Pharma has multiple technology platforms, including microbial fermentation, mammalian cell culture, gene and cell therapy, XDC & GMP facility engineering service. Empowered by PanFlex^®-Engineering, BiBo’s specialist team innovated the world’s first and largest 30,000 L stainless steel ultra-large bioreactor for mammalian cell culture production, and 30,000L high cooling capacity fermenters enabling ultra-high-cell-density fermentation.

BiBo Pharma, which started in 2014 based in Boston, USA, now has two R&D centers and three GMP facilities in operation globally. BiBo established the first GMP facility P01 site in Shanghai in 2019, the P02 GMP site in 2021, and the P03 GMP site in 2023. Two more mega-GMP facilities, P04 and P05, have been initiated and will be in operation in the next three to seven years.

BiBo’s core team members come from world-leading companies in the US, Europe, and China. BiBo has accomplished over 100 biologics projects, including over 30 in clinical and commercial stages. Our CMC service package includes cell line and strain development, process development, analytical development, formulation development, toxicological and GMP production of drug substance and drug product, process characterization, and large-scale production.

BiBo is the world leader in the fourth wave of biomanufacturing. Not only has BiBo established the world’s first and largest 30,000L ultra-large mammalian production line, but it has also achieved a 100% success rate on all scale-up projects by applying our innovative “success on the first time” system.